The link between bone disease and cardiovascular complications in hemodialysis patients

Noha Elsheikh1, Nevine Sherif1, Sameh Abou Zeid1, Mervat Eldamarawy2, Ahmed Ali2, Amal Ismail Sabry2

1 Department of Nephrology, Theodor Bilharz Research Institute, Cairo, Egypt
2 Department of Intensive Care Unit, Theodor Bilharz Research Institute, Cairo, Egypt

Type of article: Original

Abstract

Introduction: The burden on the cardiovascular system is the main cause of mortality in chronic renal patients, and bone disease, which also may cause disability, is one of the most important complications in those patients. The aim of this study was to determine the link between cardiovascular and bone disease, which frequently occur together.

Methods: In this matched case-control study, 70 subjects were subjected for full laboratory assessment as well as estimation of parathyroid hormone (PTH) level, vitamin D level, complete echocardiography, and dual energy absorptiometry. Of the 70 patients, 50 were on regular hemodialysis, and there were 20 normal controls matched with the patients with respect to age and gender.

Results: There was a significant decrease in the mean value of serum vitamin D in the hemodialysis patients, i.e., their mean value was 20.47 ± 9.60 whereas the controls had a mean value of 37.15 ± 7.67. Thus, there was a highly-significant, negative correlation between vitamin D and left ventricular mass (LVM) in the patients. We found that there was a highly-significant increase in the mean PTH levels of the patients (820.22 ± 393.51), whereas it was 57.60 ± 13.72 for the controls. The statistical significance was less than 0.001, a highly-significant increase in the mean of the T score levels in the patients (-2.15 ± 2.56), whereas it was -0.47 ± 0.71 for the controls with a statistical significance of less than 0.001. There also was a highly-significant correlation between the T score and LVM.

Conclusion: A significant correlation was found between bone disease and the occurrence of a left ventricular mass. We recommend early strict correction of the serum levels of vitamin D, PTH, calcium, and phosphorus.

Keywords: cardiovascular complication, hemodialysis, echocardiography

1. Introduction

1.1. Background and study logic

The cardiovascular burden is considered to be the main cause of mortality in chronic kidney disease (CKD). Three pathological forms of cardiovascular disease have been defined, i.e., alterations in cardiac geometry, atherosclerosis, and arteriosclerosis. Although patients with CKD have many of the risk factors that occur in the general population, there also are non-traditional, uremia-related risk factors (1). Disordered mineral metabolism may have an important role in the pathophysiology of end-stage renal disease. The parathyroid hormone level is elevated in CKD patients due to several factors that result from vitamin D deficiency, i.e., altered renal function, decreased intestinal absorption of vitamin D, and resistance to its calcemic action (2). Also, a high parathyroid level was found to contribute to increased occurrences of left ventricular masses independent of other traditional factors, and chronic elevation of this level has been associated with increased vascular calcifications and increased morbidity and mortality (2). In addition, the prevalence of osteoporosis in the population with CKD exceeds that of the general population as bone turnover is high in secondary hyperparathyroidism with osteitis fibrosa; bone resorption rates exceed bone formation rates, and osteopenia progresses to osteoporosis; in low bone turnover states, as is the case for adynamic bone disease, both bone formation and resorption rates are reduced and the loss of bone mass occurs

Corresponding author:
Dr. Sameh Abou Zeid, Department of Nephrology, Theodor Bilharz Research Institute, Cairo, Egypt.
Tel: +20.1001775574, Email: sameh.kidney@gmail.com
Received: January 17, 2016, Accepted: May 19, 2016, Published: June 2016
© 2016 The Authors. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Some researchers have stated that, paradoxically, CKD mineralization co-exists with skeletal demineralization, and this is the reason that half of the patients will have some form of cardiovascular calcification even before dialysis (4).

1.2. Objective
The objectives of this clinical trial were to evaluate the relationships between PTH, vitamin D levels, T score, and left ventricular mass in order to clarify the link between bone disease and cardiovascular complications in end-stage renal disease.

2. Material and methods
There were 70 subjects in the study, and they represented different age groups and both Genders. The 70 subjects were divided into two groups, i.e., a group of 50 patients who were on regular hemodialysis and a group of 20 healthy controls. Full medical histories were obtained for all of the subjects, and all of them underwent clinical examinations and laboratory investigations (serum urea, creatinine, serum calcium, serum phosphorus, total cholesterol, triglycerides, HDL, LDL, complete blood count, CRP, and parathyroid hormone estimation. In addition to standard M mode echocardiography, two-dimensional and pulsed wave Doppler echocardiograms were obtained soon after a session of routine hemodialysis using. Bone density was measured by Dual energy X-ray absorptiometry (DXA) scan of the femoral neck, and the results were expressed as mean ± standard deviation or number (%).

3. Results
The ages of the participants were in the range of 31-37 and 34-76 in the control and study groups, respectively. Table 1 shows a comparison of the demographic data for the case and control groups. There were significant differences between the two groups regarding age, body mass index (BMI), and smoking, but there was no significant difference in the gender of the two groups. Also, there were significant differences between the control and study groups regarding their systolic blood pressures (119.25 ± 8.17 vs. 134.33 ± 21.78), diastolic blood pressures (79.80 ± 4.26 vs. 84.33 ± 12.69), serum creatinine levels (1.21 ± 0.16 vs. 8.02 ± 2.12 mg/dl), serum urea (30.3 ± 4.32 vs. 140.27 ± 28.04 mg/dl), serum calcium (9.7 ± 0.7 vs. 9.12 ± 1.2 mg/dl), serum PO4 (3.32 ± 0.83 vs. 5.2 ± 1.78 mg/dl), serum triglyceride (152.15 ± 12.81 vs. 237.0 ± 107.5 mg/dl), serum HDL (51.1 ± 15.95 vs. 34.1 ± 20.2 mg/dl), serum albumin (3.99 ± 0.45 vs. 3.62 ± 0.48 mg/dl), serum hemoglobin (13.15 ± 1.3 vs. 10.05 ± 2.24 gm/dl), platelet count, and serum CRP (Table 1). In addition, our findings showed that there were significant differences in the T scores (-0.47 ± 0.71 vs. -2.15 ± 2.56), PTH (57.60 ± 13.72 vs. 820.22 ± 393.51), and Vitamin D (37.15 ± 7.67 vs. 20.47 ± 9.60) between two groups (p = 0.001). According to Spearman’s Rho correlation analysis, there were correlations between Left ventricular mass (LVM) and T. score, PTH, and vitamin D (p ≤ 0.001).

4. Discussion
There was a high prevalence, i.e., about 80%, of cardiovascular disease in hemodialysis patients related to age, prevalence of diabetes, and dialytic age (1). There were lower degrees of cardiovascular involvement in Stage I-IV CKD patients than in hemodialysis and peritoneal dialysis patients (2, 3). It was definitively apparent that patients with stage IIIb-IV renal disease, based on the K/DOQI CKD classification, had cardiovascular risk, as also was the case for those who underwent renal replacement therapy, i.e., hemodialysis, peritoneal dialysis, and transplants (4).

Alterations in mineral bone metabolism is associated with CKD and referred to as CKD-MBD (5). These alterations can include (a) changes in the morphology of bones, such as their volume, turnover, and mineralization; (b) abnormalities in calcium, phosphorus, PTH, vitamin D and fibroblast growth factor-23 (FGF-23); and (c) calcification of blood vessels and soft tissue (5). The current understanding of CKD–MBD indicates that phosphorus, PTH, calcium, FGF-23 (a phosphatonin hormone that is elevated in CKD to promote the renal excretion of phosphate), and vitamin D are the main regulators of mineral and bone metabolism (6). These factors are interrelated, and the parathyroid gland, kidneys, bones, and intestinal tract are the major organs that they target. Hypocalcemia, hyperphosphatemia, hyperparathyroidism, hypovitaminosis D, and elevated FGF-23 are the biochemical abnormalities that occur in CKD–MBD; even so, it is not uncommon to see significant variations, especially in serum calcium (7). Bone abnormalities in CKD include high bone turnover disease related to secondary hyperparathyroidism, i.e., osteitis fibrosa cystica; low turnover disease, i.e., adynamic bone disease; osteomalacia,
i.e., low turnover disease accompanied by undermineralized bone tissue; and mixed disease, in which features of both high and low bone turnover disease are present (8).

Table 1. Comparison between the two groups regarding their demographic characteristics, clinical examinations, and laboratory and echocardiography findings

| Variables                  | p-value |
|----------------------------|---------|
| Demographic characteristics |         |
| Age                        | 0.021   |
| Gender                     | 0.441   |
| BMI                        | 0.026   |
| Smoking                    | 0.001   |
| Clinical examinations      |         |
| Systolic blood pressure    | 0.004   |
| Diastolic blood pressure   | 0.037   |
| Pulse                      | 0.126   |
| Serum findings             |         |
| Creatinine                 | 0.001   |
| Urea                       | 0.001   |
| Calcium                    | 0.018   |
| PO4                        | 0.001   |
| Cholesterol                | 0.163   |
| Triglyceride               | 0.001   |
| HDL                        | 0.010   |
| LDL                        | 0.103   |
| Albumin                    | 0.005   |
| Hemoglobin                 | 0.001   |
| WBC                        | 0.684   |
| Platelet count             | 0.001   |
| CRP                        | 0.001   |
| Echocardiography data      |         |
| EDD (cm)                   | 0.359   |
| ESD (cm)                   | 0.002   |
| FS (%)                     | 0.037   |
| PWT (cm)                   | 0.001   |
| IVST (cm)                  | 0.001   |
| EF (%)                     | 0.003   |
| LVM                        | 0.010   |
| Wall motion abnormality    | 0.007   |
| Diastolic Dysfunction      | 0.001   |
| Pericardial effusion       | 0.169   |
| Pulmonary hypertension     | 0.022   |
| Calcification              | 0.001   |

The evidence that has been generated to date suggests that vitamin D deficiency might contribute to the extraordinarily high mortality risk among dialysis patients (9). The data from patients who have and who do not have chronic kidney disease (CKD) indicate vitamin D might protect against cardiovascular diseases, immune disorders, or cancer in addition to its classic effects on bone and mineral metabolism (10). A strong association between vitamin D deficiency and cardiovascular disease has been found in the general population (11). Lack of vitamin D influences the cardiovascular system, causing atherosclerosis, enabling vascular inflammation, endothelial dysfunction, formation of foam cells, and proliferation of smooth muscle cells, vascular calcification, fibrosis, and cardiac hypertrophy (12). It also leads to myocardial and arterial thickening and left ventricular hypertrophy (13, 14). The 25 (OH) Vitamin D was measured to find the relationship between heart and kidney disease, and, in some studies, the crosstalk between the kidney and heart. Low vitamin D levels have been associated with increased arterial stiffness and left ventricular hypertrophy (LVH) in the general population and in children with chronic kidney disease (15-17). In our study, we measured vitamin D in hemodialysis patients and controls and found a significant decrease in mean serum vitamin D in hemodialysis patients compared to controls with a mean of 20.47 ± 9.60 for HD patients vs. a mean of 37.15 ± 7.67 for controls. This is in agreement with many studies that have indicated low vitamin D levels in hemodialysis patients (9, 18, 19). Vitamin D is the substrate that
the 1α-hydroxylase enzyme in the kidney converts into 1,25(OH)₂\text{vitamin D}, the active form of vitamin D. Declining renal function is associated with reduction of renal production of 1,25(OH)₂\text{vitamin D}. However, it was discovered later that, apart from the kidney, many other organs are also able to produce 1,25(OH)₂\text{vitamin D locally}, which clearly depends on availability of the substrate vitamin D (20). So, deficiency of this substrate might be a rate limiting step in production of the active form of vitamin D in hemodialysis patients. Factors that have been suggested as a cause of vitamin D include decreased ultraviolet-B induced vitamin D production in the skin with diminished sun exposure (21). We also found a highly significant negative correlation between vitamin D and LVM in the studied patients. This is in agreement with Chang et al., who found that lower vitamin D levels were correlated with higher left ventricular mass and increased arterial stiffness in older patients (22). Earlier studies that investigated patients with CKD also showed an association between vitamin D deficiency and adverse cardiac changes, especially left ventricular hypertrophy (23, 24). Research in the molecular and cell biology areas have elucidated the role of vitamin D receptor (VDR) activation and regulation of the renin-angiotensin system (RAAS) as pathophysiologic mechanisms responsible for these changes (25-27). LV hypertrophy is an independent risk factor for mortality in adult patients with CKD, and, in these patients, regression of LV mass has been associated with survival (28). It has even been reported that nutritional supplementation with vitamin D can reverse left ventricular hypertrophy in adult CKD patients who are receiving hemodialysis (24). Parathyroid hormone abnormalities have long been recognized in CKD and hemodialysis patients. First, secondary hyperparathyroidism occurs caused by hyperphosphatemia, decreased active form of vitamin D, hypocalcemia. Prolonged hyperplasia of the parathyroid gland can cause autonomous or tertiary hyperparathyroidism. Then again, there are the treatments used that affect mineral homeostasis. Vitamin D analogues are used to treat hypocalcemia, vitamin D deficiency, and hyperparathyroidism with the possible adverse effects of producing hypercalcemia, hyperphosphatemia, and over suppression of the parathyroid gland. Parathyroid hormone levels less than 200% of the upper limit of normal out the patient at high risk of low bone turnover or adynamic bone disease. Calcimimetics are used to treat hyperparathyroidism with high or normal calcium levels, but, again, there is a risk of over suppression of the parathyroid gland (29).

In our study, we found a highly-significant increase in the mean PTH levels in our patients (820.22 ± 393.51) when compared to controls (57.60 ± 13.72) with a statistical significance of less than 0.001. There also was a highly significant positive correlation between PTH and LVM. Many studies also have demonstrated that chronically elevated PTH levels are associated with elevated cardiovascular mortality. Also, PTH levels have been associated with LVH irrespective of blood pressure effects. Secondary parathyroidism has been associated with LVH, especially if chronic uremia is present. While the exact mechanisms are unclear, PTH can stimulate the secretion of aldosterone, which is a mediator of cardiac hypertrophy. Also, PTH activates kinase C protein in cardiomyocytes, causing an increase in cellular mass. It has been noted that parathyroidectomy can cause a decrease in LV mass, and this finding supports the role of elevated PTH levels in the development of LVH (30). Patients with chronic kidney disease are exposed to another bone disease before or after developing kidney disease, i.e., osteoporosis, which is a common disease that is characterized by low bone mass and skeletal fragility resulting in an increased risk of fracture (31). However, it is difficult to diagnose osteoporosis in the setting of CKD. DXA, quantitative computed tomography, and high resolution peripheral computed tomography are imaging methods that quantify bone mass. DXA is widely available, but screening by DXA in CKD has been controversial because it cannot discriminate between cortical and trabecular bone or determine turnover or mineralization. However, recent trials have suggested that DXA of the total hip and femoral neck can predict future fractures (32). The results of this study showed a highly significant increase in mean levels of the T scores in our patients (-2.15 ± 2.56) when compared to controls (-0.47 ± 0.71) with a statistical significance of less than 0.001. There also was a highly significant positive correlation between T score and LVM. Several researchers have provided evidence of a possible correlation between cardiovascular disease and osteoporosis; in a study conducted on 180 post-menopausal women, the researchers explored the relationship between low bone mineral density and T score and coronary artery disease risk (33). Another study found increased arteriosclerosis in 558 patients, carotid and femoral pulsed wave velocity, and it seemed to be correlated with bone mineral density of the femoral neck (34). In addition, in a study conducted by Debby et al., it was reported that six of the highest ranked studies showed that there is moderate evidence that individuals with low bone mass had higher cardiovascular mortality rates than subjects with normal bone mass, and the shared common path physiology was estrogen deficiency and inflammation (35).

Acknowledgments:
The authors thank the staff members at the Theodor Bilharz Research Institute for their help in facilitating this study.
Conflict of Interest:
There is no conflict of interest to be declared.

Authors’ contributions:
All authors contributed to this project and article equally. All authors read and approved the final manuscript.

References:
1) Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004; 15(8): 2208-18. doi: 10.1097/01.ASN.0000133041.27682.A2. PMID: 15284307.
2) Harnett JD, Foley RN, Kent GM, Barre PE, Murray D, Parfrey PS. Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors. Kidney Int. 1995; 47(3): 884-90. doi: 10.1038/ki.1995.132. PMID: 7752588.
3) US Renal Data System:USRDS 2012 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2012.
4) US Renal Data System:USRDS 2009 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2009.
5) Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006; 69(11): 1945-53. doi: 10.1038/ki.2006.103. PMID: 16641930.
6) Mejia N, Roman-Garcia P, Miar AB, Tavira B, Cannata-Andia JB. Chronic kidney disease–mineral and bone disorder: a complex scenario. Nefrologia. 2011; 31(5): 514-19. doi: 10.3265/Nefrologia.pre2011. PMID: 21959717.
7) Cunningham J, Locatelli F, Rodriguez M. Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol. 2011; 6(4): 913-21. doi: 10.2215/CJN.06040710. PMID: 21454719.
8) Martin KJ, Olgaard K, Coburn JW, Coen GM, Fukagawa M, Langman C, et al. Diagnosis, assessment, and treatment of bone turnover abnormalities in renal osteodystrophy. Am J Kidney Dis. 2004; 43(3): 558-65. doi: 10.1053/ajkd.2003.12.003. PMID: 14981615.
9) Drechsler C, Verduijn M, Pilz S, Dekker FW, Krediet RT, Ritz E, et al. Vitamin D status and clinical outcomes in incident dialysis patients: results from the NECOSAD study. Nephrol Dial Transplant. 2011; 26(3): 1024-32. doi: 10.1093/ndt/gfq606. PMID: 20947538.
10) Holick MF. Vitamin D deficiency. N Engl J Med. 2007; 357(3): 266-81. doi: 10.1056/NEJMra070553. PMID: 17634462.
11) Fallo F, Catena C, Camozzi V, Luissetto G, Cosma C, Plebani M, et al. Low serum 25-hydroxyvitamin D levels are associated with left ventricular hypertrophy in essential hypertension. Nutr Metab Cardiovasc Dis. 2012; 22(10): 871-6. doi: 10.1016/j.numecd.2011.06.001. PMID: 21937207.
12) Mozos I, Marginean O. Links between vitamin D deficiency and cardiovascular diseases. Biomed Res Int. 2015; 2015: 109275. doi: 10.1155/2015/109275. PMID: 26000280, PMCID: PMC4427096.
13) Lai S, Coppola B, Dimko M, Galani A, Innico G, Frassetti N, et al. Vitamin D deficiency, insulin resistance, and ventricular hypertrophy in the early stages of chronic kidney disease. Ren Fail. 2014; 36(1): 58-64. doi: 10.3109/0886022X.2013.832308. PMID: 24028070.
14) Assalin HB, Rafacho BP, dos Santos PP, Ardisson LP, Roscani MG, Chisso-Minicucci F, et al. Impact of the length of vitamin D deficiency on cardiac remodeling. Circ Heart Fail. 2013; 6(4): 809-16. doi: 10.1161/CIRCHEARTFAILURE.112.000298. PMID: 23709660.
15) Patange AR, Valentinri RP, Gothe MP, Du W, Pettersen MD. Vitamin D deficiency is associated with increased left ventricular mass and diastolic dysfunction in children with chronic kidney disease. Pediatr Cardiol. 2013; 34(3): 536-42. doi: 10.1007/s00246-012-0489-z. PMID: 22941497.
16) Cozzolino M, Kettrler M, Zehnder D. The vitamin D system: A crosstalk between the heart and kidney. Eur J Heart Fail. 2010; 12(10): 1031-41. doi: 10.1093/eurjhf/hfq112. PMID: 20605845.
17) Sokol SI, Tsang P, Aggarwal V, Melamed ML, Srinivas VS, et al. Vitamin D status and risk of cardiovascular events: lessons learned via systematic review and meta-analysis. Cardiol Rev. 2011; 19(4): 192-201. doi: 10.1097/CRD.0b013e31821da9a5. PMID: 21646873.
18) Pecovnik-Balon B, Jakopin E, Bevc S, Knehtl M, Gorenjak M. Vitamin D as a Novel Nontraditional Risk Factor for Mortality in Hemodialysis Patients. Ther Apher Dial. 2009; 13(4): 268-72. doi: 10.1111/j.1744-9987.2009.00722.x. PMID: 19695057.

19) Wolf M, Shah A, Gutierrez O, Ankers E, Monroy M, Tamez H, et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int. 2007; 72(8): 1004-13. doi: 10.1038/sj.ki.5002451. PMID: 17687259.

20) Peterlik M, Cross HS. Vitamin D and calcium deficits predispose for multiple chronic diseases. Eur J Clin Invest. 2005; 35(5): 290-304. doi: 10.1111/j.1365-2362.2005.00487.x. PMID: 15860041.

21) Barreto DV, Barreto FC, Liabeuf S, Temmar M, Boitte F, Choukroun G, et al. Vitamin D Affects Survival Independently of Vascular Calcification in Chronic Kidney Disease. Clin J Am Soc Nephrol. 2009; 4(6): 1128-35. doi: 10.2215/CJN.00260109. PMID: 19443628, PMCID: PMC2689889.

22) Chang J, Ye XG, Hou YP, Wu JL, Li SL, Sun QM. Vitamin D Level is Associated with Increased Left Ventricular Mass and Arterial Stiffness in Older Patients with Impaired Renal Function. Med Sci Monit. 2015; 21: 3993-9. PMID: 26691016, PMCID: PMC4692575.

23) Artaza JN, Mehrotra R, Norris KC. Vitamin D and calcium deficits predispose for multiple chronic diseases. Eur J Clin Invest. 2005; 35(5): 290-304. doi: 10.1111/j.1365-2362.2005.00487.x. PMID: 15860041.

24) Matias PJ, Jorge C, Ferreira C, Borges M, Aires I, Amaral T, et al. Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimension parameters. Clin J Am Soc Nephrol. 2010; 5(5): 905-11. doi: 10.2215/CJN.06510909. PMID: 20203163, PMCID: PMC2863968.

25) Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest. 2002; 110(2): 229-38. doi: 10.1172/JCI021521. PMID: 12122115, PMCID: PMC151055.

26) Nibbelink KA, Tishkoff DX, Hershey SD, Rahman A, Simpson RU. 1,25(OH)2-vitamin D3 actions on cell proliferation, size, gene expression, and receptor localization in the HL-1 cardiac myocyte. J Steroid Biochem Mol Biol. 2007; 103(3-5): 533-7. doi: 10.1016/j.jsbmb.2006.12.099. PMID: 17276054, PMCID: PMC1890037.

27) Wu J, Garami M, Cheng T, Gardner DG. 1,25(OH)2-vitamin D3 and retinoic acid antagonize endothelin-stimulated hypertrophy of neonatal rat cardiac myocytes. J Clin Invest. 1996; 97(7): 1577-88. doi: 10.1172/JCI118582. PMID: 8601621, PMCID: PMC507220.

28) London GM, Pannier B, Guerin AP, Blacher J, Marchais SJ, Darne B, et al. Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: follow-up of an interventional study. J Am Soc Nephrol. 2001; 12(12): 2759-67. PMID: 11729246.

29) National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis. 2002; 39(2 Suppl 1): 1-266. PMID: 11904577.

30) Leibowitz D. Left Ventricular Hypertrophy and Chronic Renal Insufficiency in the Elderly. Cardiorenal Med. 2014; 4(3-4): 168-175. doi: 10.1159/000366455. PMID: 25737681, PMCID: PMC4299265.

31) Riggs BL, Melton LJ 3rd. The world wide problem of osteoporosis: insights offered by epidemiology. Bone. 1995; 17(5): 505-11. doi: 10.1016/8756-3282(95)00258-4. PMID: 8573428.

32) Limori S, Mori y, Akita w, Kuyama T, Takada S, Asai T, et al. Diagnostic usefulness of bone mineral density and biochemical markers of bone turnover in predicting fracture in CKD stage 5patients. a single cohort study. Nephrol Dial Transplant. 2012; 27(1): 345-51. doi: 10.1093/ndt/gfr317. PMID: 21652550.

33) Alissa EM, Alnahdi W, Alam N, Ferns GA. Bone mineral density and cardiovascular risk factors in post menopausal women with coronary artery disease. Bone key rep. 2015; 4: 758. doi: 10.1038/bonekey.2015.127. PMID: 26587227, PMCID: PMC4644069.

34) Avramovski P, Avramovska M, Sikole A. Bone Strength and Arterial Stiffness Impact on Cardiovascular Mortality in a General Population. J Osteoporosa. 2016; 2016: 7030272. doi: 10.1155/2016/7030272. PMID: 27047700, PMCID: PMC4800107.

35) den Uyl D, Nurmohamed MT, van Tuyl LH, Raterman HG, Lems WF. (Sub)clinical cardiovascular disease is associated with increased bone loss and fracture risk; a systematic review of the association between cardiovascular disease and osteoporosis. Arthritis Res Ther. 2011; 13(1): 5. doi: 10.1186/ar3224. PMID: 21241491, PMCID: PMC3241350.